LCM
RYTM icon

Laurion Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Laurion Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,322
Closed -$68K – 593
2022
Q2 		$68K Buy
+16,322
New +$89.3K ﹤0.01% 408
2018
Q3 		– Sell
-84,200
Closed -$2.63M – 1501
2018
Q2 		$2.63M Buy
+84,200
New +$2.3M 0.02% 532
2018
Q1 		– Sell
-55,500
Closed -$1.61M – 1642
2017
Q4 		$1.61M Buy
+55,500
New +$1.47M 0.01% 843

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Laurion Capital Management's RYTM Position: Q3 2022 in Review

Laurion Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2022, closing a stake of 16,322 shares — an estimated $68K sold.

Laurion Capital Management first reported a position in RYTM in Q4 2017 and held it in 3 quarters. The position peaked at $2.63M in Q2 2018. 101 funds tracked by Wall St. Rank hold RYTM as of Q3 2022.

  • Laurion Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Laurion Capital Management sold 16,322 Rhythm Pharmaceuticals shares in Q3 2022, an estimated $68K.
  • Laurion Capital Management first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Laurion Capital Management's Rhythm Pharmaceuticals position peaked at $2.63M in Q2 2018.
  • 101 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2022.

Based on Laurion Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.